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Abstract
Antidepressants are an effective treatment for depressive and anxiety disorders. Those disorders
are frequently accompanied by heightened cortisol levels. Antidepressants may affect
hypothalamic–pituitary–adrenal axis functioning, the alteration of which could be partially
responsible for treatment efficacy. The association between antidepressants and cortisol was
investigated in 1526 subjects of the Netherlands Study of Depression and Anxiety who were
grouped into ‘serotonin reuptake inhibitor (SSRI) users’ (n=309), ‘tricyclic antidepressant (TCA)
users’ (n=49), ‘other antidepressant users’ (n=100), and ‘non-users’ (n=1068). All subjects had
a current or past diagnosis of anxiety and/or depression. Subjects provided 7 saliva samples from
which 3 cortisol indicators were calculated: cortisol awakening response (CAR), evening cortisol,
and cortisol suppression after ingestion of 0.5 mg dexamethasone. As compared to non-users,
TCA users had a flattened CAR (effect size: Cohen's d=0.34); SSRI users had higher evening
cortisol levels (d=0.04); and SSRI users showed decreased cortisol suppression after
dexamethasone ingestion (d=0.03). These findings suggest that antidepressant subtypes are
associated with distinct alterations of the HPA axis. TCA users, who showed a flattened CAR,
displayed the strongest alterations of salivary cortisol.
© 2011 Elsevier B.V. and ECNP. All rights reserved.University Medical Center,
9600, 2300 RC Leiden, The
: +31 71 5248156.
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A hyperactive hypothalamic–pituitary–adrenal (HPA) axis,
indicated by increased cortisol levels (Bhagwagar et al., 2005),
has frequently been found in subjects with depressive and
anxiety disorders. Antidepressants used to treat depressionts reserved.
692 L. Manthey et al.and anxiety (Rose, 2007) may influence HPA axis activity
through changes to the glucocorticoid (GRs) and mineralocor-
ticoid receptors (MRs) (Bjartmar et al., 2000). These altera-
tions could be partially responsible for treatment efficacy
(Pariante, 2009). Furthermore, increased cortisol levels have
been found to be associatedwith a number of physical diseases
(e.g., diabetes, osteoporosis) (Bruehl et al., 2007; Nieman,
2007) which often co-occur with depression and/or anxiety
(Nouwen et al., 2010). It is unclear whether antidepressant
treatment affects physical diseases in anxious and depressed
subjects through modified cortisol levels. For these reasons,
studying the effects of antidepressants on the HPA axis is
clinically important. However, research on cortisol levels in
antidepressant users has yielded results that differed by
antidepressant type and cortisol measure.
Studies were typically limited to a small number of sub-
jects with a diagnosis of depression and the average duration
of intervention was five or six weeks (Deuschle et al., 2003).
In these studies, TCA treatment usually (Deuschle et al.,
1997), but not always (Dam, 1988), resulted in increased
cortisol suppression in the dexamethasone suppression test
(DST) which measures HPA axis response to the administra-
tion of a synthetic analog of cortisol. TCA responders had
more strongly suppressed cortisol levels at morning, after-
noon, and evening time points (Deuschle et al., 2003) than
SSRI responders. Long-term SSRI use decreased cortisol and
normalized cortisol suppression in one study (Aihara et al.,
2007) but not in another (Vythilingam et al., 2004). In a third
study, SSRI treatment did not decrease salivary cortisol re-
gardless of remitted or non-remitted status post-treatment
(Weber-Hamann et al., 2007). In contrast to the putative HPA
axis dampening effects resulting from longer term use, short-
term TCA and SSRI use was found to activate the HPA axis
(Holsboer and Barden, 1996). Research on the associations of
non-TCA/non-SSRI antidepressant medications and HPA axis
function was limited to one study in which tetracyclic anti-
depressants and selective serotonin reuptake enhancers
reduced previously increased corticosterone secretion in
stressed rats (Szymanska et al., 2009).
Research on antidepressants and cortisol in anxious sub-
jects was even more scarce. Increased cortisol levels have
been associated with some types of anxiety, both in our own
work group (Vreeburg et al., 2010) and in other studies
(Mantella et al., 2008), though these results have been
inconsistent. Antidepressants such as SSRIs and TCAs have
been effective treatments for anxiety disorders (Baldwin
et al., 2005) and might lower cortisol levels in anxious
patients as it has been shown to do in depressed subjects
(Deuschle et al., 1997). Though chronic antidepressant use
is common, the long-term effects (≥12 months) have not
been well studied. More importantly, we were not aware of
studies that compared the effects of different groups of
antidepressants on cortisol indicators.
A fuller understanding of the biological mechanism under-
lying the effects of antidepressants could result in improved
treatment options for anxious and depressed patients. We
present a cross-sectional study which compares salivary cor-
tisol levels in TCA, SSRI, other antidepressant and non-users
with a lifetime diagnosis of a depressive and/or an anxiety
disorder participating in the Netherlands Study of Depression
and Anxiety (NESDA). Based on the literature, we expected
to find altered cortisol indicators (decreased CAR, lowerbasal evening levels, and increased suppression in the DST) in
antidepressant users compared to non-users.
2. Experimental procedures
2.1. Subjects
Subjects participated in the Netherlands Study of Depression and
Anxiety (NESDA), a longitudinal cohort study consisting of 2981 re-
spondents recruited from the community, general practices, and
specialized mental health care institutions. Objectives and methods
of the NESDA project have been described in an earlier publication
(Penninx et al., 2008). Subjects completed a baseline measurement
consisting of a medical exam, an in-person interview, collection of
saliva samples, and questionnaires. The study protocol was approved
by the Ethical Review Board of each participating center and all
subjects signed an informed consent form before participation.
To evaluate the associations between antidepressant use and
salivary cortisol, only subjects reporting a current or past diagnosis of a
depressive and/or anxiety disorder (referred to as a lifetime disorder)
were included. The presence of a depressive disorder (Major De-
pressive Disorder [MDD] or dysthymia) or anxiety disorder (generalized
anxiety disorder, social phobia, or panic disorder) was assessed by the
DSM-IV Composite Interview Diagnostic Instrument (WHO version 2.1).
As previous research in our study group showed that remitted de-
pressed and anxious subjects had a marginally heightened CAR
(Vreeburg et al., 2009a; Vreeburg et al., 2010), indicating an increased
biological vulnerability, those with a past diagnosis of either disorder
were also included. In addition to subjects without lifetime disorders
(n=687), subjects who lacked cortisol data (n=636), used corticoster-
oids (n=105), were pregnant or breastfeeding (n=10), or reported
irregular antidepressant use (n=17) were excluded (Vreeburg et al.,
2009a).
The remaining subjects (n=1526) were available for analysis. All
subjects who had used any antidepressant medication in the month
prior to the baseline interview (n=458) were defined as antidepres-
sant users and further subdivided into SSRI users, TCA users, and
other antidepressant users. Subjects who had not used antidepres-
sants in the month prior to baseline interview were defined as non-
users (n=1068). Of the non-users, 15% reported some antidepressant
use in the past 3 years. The following groups resulted: 309 SSRI users,
49 TCA users, 100 other antidepressant users, and 1068 non-users.
2.2. Measures of antidepressant use
Medication use during the month prior to the baseline assessment
was assessed via medication containers brought to the interview
(80.7%) and subject self-report. Antidepressant users provided in-
formation on the daily dose, frequency of use, duration of treat-
ment, and type of antidepressant used.
Antidepressants were classified as SSRIs (ATC codes N06AB02–
N06AB10), TCAs (ATC codes N06AA01–N06AA23), and other antide-
pressants (ATC codes N06AX05, N06AX11, N06AX16, and N06AX21,
including tetracyclic antidepressants [n=25], serotonin–norepineph-
rine reuptake inhibitors [n=82], and trazodone [n=1]), indicating that
8 subjects took more than one 'other' antidepressant. Due to small
group sizes, the other AD user group was not further subdivided. For
those reporting the use of multiple antidepressants, we assigned
subjects to one of the three user groups based on relative strengths of
the prescribedmedications. SSRIs are usually prescribed as first-choice
treatment for MDD as they have a milder side effect profile than TCAs
but similar efficacy in moderately depressed patients. In severely
depressed patients, or in thosewho do not tolerate the adverse effects
of SSRIs or donot improvewith SSRI treatment, TCAs are recommended
(Peretti et al., 2000). Using this information, subjects taking both a
TCA and another type of antidepressant (n=5) remained in the TCA
user group as TCAs are believed to have stronger effects than other
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antidepressant (n=10) were classified as SSRI users.
In order to compare dosages of different antidepressants, the
Mean Daily Dose for each user was calculated by dividing the milli-
grams of antidepressant used daily by the Defined Daily Dose as
defined by the World Health Organization for each antidepressant.
2.3. Cortisol measures
A detailed description of cortisol measures can be found elsewhere
(Vreeburg et al., 2009b). To summarize, respondents collected saliva
samples at home on a regular, preferably working, day shortly after
the baseline interview was conducted. Subjects were instructed to
refrain from eating, smoking, drinking tea or coffee, or brushing
teeth 15 min prior to sampling and no dental work was allowed in the
24 h preceding sample collection. Seven saliva samples were col-
lected over a two-day period using Salivettes© (Sarstedt, Germany).
On day 1, samples were taken at awakening (T1) and at 30 min (T2),
45 min (T3), and 60 min (T4) post-awakening. Two samples were
taken in the evening at 22:00 h (T5) and 23:00 h (T6). Subjects
ingested 0.5 mg of dexamethasone immediately after T6 and one
salivary sample was taken at awakening on day 2 (T7). Samples were
refrigerated after collection and returned by mail. In the laboratory,
Salivettes were centrifuged at 2000 g for 10min, aliquoted, and stored
at −80 °C and cortisol analysis was carried out using competitive
electrochemiluminescence immunoassay (Roche, Switzerland).
The functional detection limit was 2.0 nmol/l and the intra- and
interassay variability coefficients in the measuring range were less
than 10%.
The following three cortisol indicators were calculated from the
seven cortisol samples.
Cortisol awakening response (CAR): The CAR was calculated by
analysis of T1 to T4 with linear mixed models (LMM) and two
aggregate indicators: the area under the curve with respect to
the ground (AUCG) and the area under the curve with respect to
the increase (AUCI) (Pruessner et al., 2003). The AUCG is an
estimate of the total cortisol secretion during the first hour after
awakening. The AUCI is a measure of the dynamic of the cortisol
awakening response, related to the sensitivity of the system,
emphasizing changes over time.
Evening cortisol: The basal cortisol level was defined as the
average of the two evening cortisol values (T5 and T6). For subjects
with a single missing evening value, the remaining cortisol value
was used.
Dexamethasone suppression test (DST): In addition to the cortisol
level at awakening after dexamethasone ingestion (T7), a
cortisol suppression ratio was calculated by dividing the cortisol
level at awakening on day 1 (T1) by the post-dexamethasone
cortisol level at awakening on day 2 (T7). Higher DST ratios
indicated a larger difference between T1 and T7 and, accord-
ingly, a greater cortisol-suppressing effect of dexamethasone.
2.4. Covariates
The four categories of confounding variables were: sociodemo-
graphic indicators, psychiatric indicators, health indicators, and
sampling factors. These variables altered cortisol levels in previous
analyses of the NESDA data (Vreeburg et al., 2009b). A detailed
description is located in additional publications (Penninx et al.,
2008; Vreeburg et al., 2009a).
Sociodemographic indicators included age, sex, and level of
education. Psychiatric indicators consisted of a lifetime diagnosis of
comorbid anxiety and depression as subjects with comorbid disorder
were found to have a higher CAR in previous research in this study
group (Vreeburg et al., 2009a). The Inventory of Depressive
Symptomatology Self-Report (IDS-SR), a rating scale for depressionseverity, was not associated with cortisol levels in NESDA (Vreeburg
et al., 2009b). However, as the sample used in our analyses was
slightly different to the one defined previously, the IDS-SR was
included as a covariate in a sensitivity analysis. In order to account
for possible associations between cortisol and anxiety severity, we
also included the Beck Anxiety Questionnaire as covariate in a
separate sensitivity analysis. Health indicators included tobacco use
and the current level of physical activity. Tobacco use was grouped
into current smokers, former smokers, and non-smokers. Addition-
ally, the number of smoked cigarettes per day was counted in order
to exclude the heavy smokers (defined as smoking N25 cigarettes/
day) in a sensitivity analysis. Physical activity was measured using
the International Physical Activity Questionnaire and expressed in
1000 MET-minutes per week.
Sampling factors included seasonal light, weekday or weekend
status, work status, awakening time, and hours of sleep per night.
Seasonal light was evaluated by defining the month of sampling
as either a dark month (October through March) or a light month
(April through September). Average sleep duration during the
four weeks prior to sampling was categorized as ≤6 or N6 h per
night.2.5. Statistical analyses
Characteristics of study groups were expressed by frequencies or
means and compared using χ2 statistics (categorical variables) or
analysis of variance (continuous variables). Positively skewed cortisol
indicators (T1–T4, AUCG, evening cortisol, T7 and DST) were naturally
log-transformed for subsequent analyses. Back-transformed values are
given in Table 2. Post-hoc tests on individual group differences were
performed using the Fisher Least Significant Difference test. Differ-
ences in AUCG, AUCI, evening cortisol, T7, and DST across groups were
analyzed using analysis of covariance (ANCOVA), adjusting for
covariates. Cohen's d (the difference in marginal estimated means,
divided by their pooled standard deviation) was calculated as a
measure of effect size.
Further analysis of the CAR was carried out with random
coefficient analysis of the four morning cortisol data points using
Linear Mixed Models (LMM). LMM retains original values on all data
points while accommodating for missing data and taking into account
correlations between repeated measurements within subjects.
Linear regression analyses on dosage of antidepressant (Mean
Daily Dose) and duration of use (months) were conducted on the SSRI
and TCA user groups. Other AD users were excluded from these
analyses due to the multiple antidepressants types included in this
group. Analyses were adjusted for the described covariates. To
determine the stability of our results, all analyses were also
corrected for severity of depression and anxiety in sensitivity
analyses. Additionally, heavy smokers (defined as smoking N25
cigarettes/day), users of multiple antidepressants, and lithium users
were excluded in different sensitivity analyses in order to
investigate the robustness of our results. Statistical significance
was set at pb0.05. SPSS 16.0 software was used for all analyses (SPSS
Inc, Chicago, Ill.).3. Results
Characteristics of the study groups are shown in Table 1. TCA
users were older than SSRI users, other users, and non-users.
Non-users were more likely to have sampled during a light
month and on a working day. Antidepressant users more often
had comorbid anxiety and depression than non-users. TCA users
used smaller antidepressant doses than the other groups.
Results of analyses of covariance are shown in Table 2.
Table 1 Characteristics of study groups (n=1526).
N SSRI users
(n=309)
TCA users
(n=49)
Other AD users
(n=100)
Non-users
(n=1068)
P-value
Sociodemographics 1529
Age 1529 42.8 (41.5–44.1)a 48.9 (46.3–51.4)a,b,c 43.8 (41.8–45.9)b 43.1 (42.3–43.9)c 0.01
% Male 1529 33.7 26.5 40.0 32.3 0.33
Years of education 1529 11.6 (11.2–12.0) 11.4 (10.5–12.3) 11.9 (11.2–12.6) 11.9 (11.7–12.1) 0.68
Sampling factors 1529
% Sampled during light months 1529 53.7 49.0 48.0 59.0 0.05
% Sampled on weekday 1529 90.0 89.8 90.0 92.4 0.47
% sampled on work day 1529 52.1 51.0 55.0 63.0 0.002
Awakening time 1529 7 h 36 min
(7 h 28 min–7 h 45 min)
7 h 30 min
(7 h 12 min–7 h 48 min)
7 h 31 min
(7 h 17 min–7 h 45 min)
7 h 27 min
(7 h 23 min–7 h 32 min)
0.35
% N6 h per night 1529 72.8 69.4 71.0 69.4 0.71
Health indicators 1529
Tobacco use 1529 0.11
% Former smoker 1529 32.4 38.8 29.0 38.4
% Current smoker 1529 39.8 44.9 40.0 34.4
Level of physical activity1 (in MET-minutes) 1529 22.6 (19.9–25.5)a 22.1 (16.7–29.0) 20.0 (16.1–24.8)b 27.2 (25.7–28.7)a,b 0.001
Psychiatric indicators 1529
Lifetime diagnosis 1529 b0.001
% Depressive disorder only 1529 22.3 12.2 22.0 33.2
% Anxiety disorder only 7.4 12.2 5.0 18.2
% Comorbid anxiety/depressive disorder 1529 70.2 75.5 73.0 48.6
Severity of psychopathology
IDS-SR Mood/Cognition Subscale 1526 8.3 (7.81–8.87)a 7.6 (6.21–8.93)b 8.6 (7.7–9.5)c 6.3 (6.0–6.5)a,b,c b0.001
IDS-SR Anxiety/Arousal Subscale 1526 5.8 (5.5–6.1)a 6.1 (5.4–6.9)b 4.9 (4.7–5.1)c 4.9 (4.7–5.1)a,b,c b0.001
Beck Anxiety Questionnaire 1520 13.1 (12.0–14.3)a 14.0 (11.4–17.1)b 12.9 (10.8–15.3)c 9.0 (8.6–9.5)a,b,c b0.001
Antidepressant use
Duration of use (mean in months, 95% C.I.) 455 14.4 (12.3–16.9) 19.0 (12.1–29.3)a 11.7 (9.2–14.7)a – 0.12
Daily dosage level2 (mean, 95% C.I.) 455 1.2 (1.2–1.2)a,b 1.0 (0.9–1.1)a,c 1.1 (1.1–1.2)b,c – b0.001
IDS-SR indicates Inventory of Depressive Symptomatology Self-Report.
P-value was calculated by analysis of variance (ANOVA) or the χ2 test. Significance is inferred at Pb0.05. Numbers in bold indicate a significant P value. Matching superscript letters are given for
values that differ significantly within a row (post-hoc test, Pb0.05).
CI = confidence interval, SSRI = selective serotonin reuptake inhibitor, TCA = tricyclic antidepressant, and AD = antidepressant.
For duration of use, dosage and physical activity back-transformed means (95%C.I.s) are presented, based on estimated marginal means.
1MET-minute = (Metabolic Equivalent minute), multiple of the resting metabolic rate.
2A comparative daily dosage level (stated as Mean Daily Dose) was calculated by dividing the milligrams of antidepressant used daily by the defined daily dosage (DDD) for the specific
antidepressant.
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Table 2 Associations between antidepressant use and salivary cortisol indicators (n=1526).
Cortisol characteristics N SSRI users
(n=309)
SSRI users vs.
non-users
TCA users
(n=49)
TCA users vs.
non-users
Other AD users
(n=100)
Other AD users vs.
non-users
Non-users
(n=1068)
Mean (C.I. 95%) P-value Mean (C.I. 95%) P-value Mean (C.I. 95%) P-value Mean (C.I. 95%)
Unadjusted values
Cortisol awakening response (CAR)
Cortisol T1 (awakening, nmol/l) 1512 15.8 (15.1–16.5) 0.84 18.3 (16.4–20.5) 0.009 15.6 (14.4–16.9) 0.92 15.7 (15.3–16.1)
Cortisol T2 (+30 min, nmol/l) 1495 19.8 (18.9–20.9) 0.48 18.1 (15.9–20.4) 0.25 19.0 (17.4–20.7) 0.57 19.5 (19.0–20.0)
Cortisol T3 (+45 min, nmol/l) 1481 18.6 (17.6–19.6) 0.23 18.4 (16.4–20.6) 0.54 18.7 (17.0–20.5) 0.40 17.9 (17.4–18.4)
Cortisol T4 (+60 min, nmol/l) 1491 16.0 (15.1–16.8) 0.56 16.9 (14.7–19.3) 0.31 16.0 (14.5–17.6) 0.67 15.7 (15.2–16.1)
AUCG (nmol/l/h) 1464 18.5 (17.7–19.3) 0.32 18.9 (17.0–21.0) 0.42 18.0 (16.7–19.4) 0.99 18.0 (17.6–18.5)
AUCI (nmol/l/h) 1464 2.7 (2.0–3.4) 0.56 0.09 (−1.7–1.9) 0.01 2.3 (1.0–3.5) 0.78 2.5 (2.1–2.8)
Evening cortisol (nmol/l/h) a 1520 5.3 (5.0–5.6) 0.007 5.8 (5.0–6.7) 0.02 5.3 (4.8–5.9) 0.09 4.8 (4.7–5.0)
Dexamethasone suppression test (DST)
Cortisol T7 (awakening day 2, nmol/l) 1470 7.3 (6.9–7.7) 0.001 8.5 (7.4–9.7) b0.001 7.3 (6.7–8.1) 0.03 6.5 (6.4–6.7)
Cortisol suppression ratio (nmol/l) b 1457 2.3 (2.2–2.5) 0.001 2.4 (2.0–2.8) 0.29 2.3 (2.0–2.5) 0.02 2.6 (2.5–2.7)
Adjusted values c
AUCG (nmol/l/h) 1464 18.5 (17.8–19.3) 0.33 18.4 (16.5–20.4) 0.72 17.9 (16.6–19.3) 0.81 18.0 (17.6–18.5)
AUCI (nmol/l/h) 1464 2.8 (2.1–3.5) 0.41 0.2 (−1.6–2.1) 0.03 2.4 (1.1–3.7) 0.88 2.4 (2.0–2.8)
Evening cortisol (nmol/l) 1520 5.3 (5.0–5.6) 0.02 5.6 (4.9–6.5) 0.05 5.3 (4.8–5.8) 0.18 4.9 (4.7–5.0)
Cortisol T7 (awakening day 2, nmol/l) 1470 7.2 (6.9–7.7) 0.003 8.2 (7.1–9.3) 0.002 7.2 (6.6–7.9) 0.08 6.6 (6.4–6.8)
Cortisol suppression ratio (nmol/l) 1457 2.3 (2.2–2.5) 0.002 2.4 (2.1–2.8) 0.37 2.3 (2.1–2.5) 0.05 2.6 (2.5–2.7)
SSRI = selective serotonin reuptake inhibitor, TCA = tricyclic antidepressant, AD = antidepressant, AUCG = area under the morning curve with respect to the ground, AUCI = area under the
morning curve with respect to the increase, T = time point, and CI = confidence interval.
For all cortisol indicators except for AUCI backtransformed means (95%C.I.s) are presented, based on estimated marginal means, calculated by analysis of covariance (ANCOVA). For AUCI
estimated marginal means (95%C.I.s) are presented. P-values are calculated by ANCOVA comparing two groups at a time. Significance is inferred at Pb0.05. Numbers in bold indicate a
significant P value.
a The evening cortisol level is the average of T5 and T6 (taken at 22:00 h and 23:00 h).
b The cortisol suppression ratio is the ratio of salivary cortisol at T1 to salivary cortisol at T7 after 0.5 mg dexamethasone.
c Adjusted for sociodemographic variables (sex, age, education), psychiatric indicators (comorbidity), health indicators (smoking and physical activity), and sampling factors (seasonal light,
work status, weekday/weekend, awakening time, sleep).
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696 L. Manthey et al.3.1. Cortisol awakening response
A large percentage of the TCA users (42.9%) did not show the
characteristic increase in cortisol in the first hour of awakening
as compared to only 26.2% of SSRI users, 33.0% other AD users,
and 28.1% non-users. Adjusted CAR results showed that TCA,
SSRI, and other AD users did not differ from non-users on overall
cortisol levels, reflected by analysis of AUCG and a non signi-
ficant group effect in LMM analysis (F (3,1500)=0.14, p=0.94).
The time course of the awakening response of TCA users
differed from that of non-users aswell as of SSRI users and other AD
users, reflected by analysis of AUCI (effect size [Cohen's d]=0.34,
p=0.03, TCA users vs. non-users, see Table 2) and a significant
group * time interaction in the LMM analysis (F (3,3268)=4.53,
p=0.004; TCA users vs. non-users, data not shown). As can be seen
in Fig. 1, TCA users had a considerably flattened CAR compared to
all other groups. None of the other antidepressant user groups
differed from the non-user group on the AUCI.3.2. Evening cortisol
Unadjusted and adjusted evening cortisol levels were signifi-
cantly higher for SSRI users (d=0.04, p=0.02) and marginally
significant for TCA users (effect size=0.17, p=0.05) as compared
to non-users. Other AD users did not differ from non-users.3.3. Dexamethasone suppression test
After adjustment for covariates, T7 cortisol levels in SSRI and TCA
users were higher (SSRI vs. non-users: d=0.19, p=0.003; TCA vs.
non-users: d=0.46, p=0.002) but other AD users differed only
marginally from non-users at T7.
Unadjusted and adjusted cortisol suppression ratios were
lower in SSRI users (d=0. 03, p=0.002) and marginally significant
in other AD users (d=0.22, p=0.05) as compared to non-users,Awakening 30
min
22:00 
h
Day 2:
Post-Dex
0
5
10
15
20
SSRI users
TCA users
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45
min
60
min
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Figure 1 Mean salivary cortisol levels of the CAR, evening
cortisol and cortisol after dexamethasone administration adjusted
for sociodemographic variables, psychiatric indicators, health
indicators, and sampling factors. Numerical values for cortisol
indicators are shown.indicating a smaller cortisol suppressing effect of dexametha-
sone.
Consistent results were found for SSRI users (vs. non-users),
who had both higher T7 values and the expected lower cortisol
suppression ratio. For the TCA users, results of the DST and T7
were incongruous. TCA users had higher T7 values, but a non-
statistically significant lower cortisol suppression ratio. As the
number of subjects using TCAs was much smaller than in the
SSRI group, type II errors could have occurred for the latter
contrasts. Due to these discrepancies between T7 and the DST
in the TCA group, no conclusions could be drawn on basis of
these findings and only the suppression findings of the SSRI
group (which were consistent across cortisol indicators) were
considered in the discussion.
Additional adjustment for severity with the IDS-SR and BAI as
well as the exclusion of multiple antidepressant users, lithium
users, and heavy smokers did not significantly alter the results
in any of the conducted analyses (data not shown).
3.4. Antidepressant dose and duration
In the linear regression analyses, performed in SSRI and TCA
users separately (n=358), dosage level or duration of use was
not associated with cortisol indicators (data not shown).
4. Discussion
In this study, the relationship between antidepressant use
and multiple salivary cortisol measures was investigated in
1526 NESDA participants with a lifetime diagnosis of de-
pression and/or anxiety. As compared to non-users, TCA
users had a flattened CAR, SSRI users had higher evening
cortisol levels, and SSRI users displayed a lower suppressing
effect of dexamethasone.
Though previous studies have linked lower morning cor-
tisol levels at a single time point with TCA use (Deuschle
et al., 2003), the association between TCA use and the CAR
has not previously been studied. However, the atypical AUCI
pattern seen in the majority of TCA users in our study is
unlikely to indicate that TCAs are clinically effective by
producing a flattened CAR. As the CAR is commonly viewed as
a healthy reaction to awakening, with awakening represent-
ing a natural stressor (Kuehner et al., 2007), the atypical
curve most probably reflects an impaired ability to react to
the stress of awakening in more severely depressed and
difficult-to-treat subjects for whom TCAs are prescribed.
A biological explanation for the atypical curvemay lie in the
effects of antidepressants on the two main corticosteroid
receptors, GR andMR (Bjartmar et al., 2000). GRs are assumed
to restore corticosteroid homeostasis after circadian peaks.
Consequently, increased expression of GR may increase
suppression of cortisol levels (Eiring and Sulser, 1997). Most
animal studies (Johansson et al., 1998), but not all of them
(Pariante et al., 2003), found that chronic TCA administration
resulted in upregulation of GRs, which might contribute to the
observed flattened CAR. Additionally, the MR was recently
identified as a modulator of the CAR (De Rijk et al., 2006) and
found to be upregulated after chronic TCA administration in
many (Bjartmar et al., 2000), but not all (Przegalinski and
Budziszewska, 1993), animal studies. Thus the MR may also
contribute to the flattened CAR. However, the total cortisol
697Antidepressant use and salivary cortisol in depressive and anxiety disorderssecretion during the first hour after awakening (i.e., AUCG)
was not reduced in TCA users as compared to non-users.
Therefore, an increased sensitivity to corticosteroids in re-
sponse to TCAs is unlikely to be the sole biological explanation
for our findings.
We observed higher basal cortisol levels and decreased
cortisol suppression in SSRI users. Previous studies reported
lower (Vythilingam et al., 2004) or unchanged (Deuschle et
al., 2003; Juruena et al., 2010) basal levels and variously
altered (decreased, increased and unchanged) cortisol
suppression in users (Aihara et al., 2007; Deuschle et al.,
2003; Vythilingam et al., 2004; Watson et al., 2006). There
are several possible explanations for these discrepancies.
Associations of reduced cortisol levels with a positive
treatment response (Deuschle et al., 2003) indicated that
normalized cortisol levels may not reflect antidepressant use
alone. On the other hand, in NESDA (Vreeburg et al., 2009a)
and other studies, (Bhagwagar et al., 2003) elevated cortisol
levels were found in both current and remitted depressed
subjects and an intervention reported no association be-
tween suppression after prednisolone administration and
treatment response (Juruena et al., 2010). Altered HPA axis
activity may reflect a biological vulnerability (Juruena et al.,
2010), independent of treatment success (Vreeburg et al.,
2009a). However, an intervention study found that impaired
response to the prednisolone suppression test was associated
with treatment resistance (Juruena et al., 2009). Therefore,
additional randomized intervention studies are needed in
order to investigate the relationship between the different
cortisol indicators and treatment response.
Alternatively, the cortisol-reducing effects of antidepres-
sants in intervention studies may be temporary, implying that
conflicting findings were due to inter-study differences in
treatment duration. Indeed, an animal study showed the up-
regulating effect of antidepressants on MR and GR receptor
levels to be transient in nature (Reul et al., 1993). In contrast
to the five or six weeks of treatment in intervention studies
(Deuschle, 2003), 88.5% of NESDA users reported at least two
months of antidepressant use and 47.1% of users reported
chronic use (≥12 months). However, as we found an altered
CAR in TCA users, the majority of whom were chronic users,
altered stress responses might persist in TCA users. Further-
more, dampening of the HPA axis has been hypothesized to be
related to therapeutic efficacy of antidepressants (Pariante,
2009) and antidepressants have been shown to be an effective
long-term treatment. The long-term effects of antidepres-
sants on cortisol need further investigation in prospective
studies before firm conclusions can be drawn.
Alternatively, the discrepancies of our results with
previous findings could be due to the inclusion of subjects
with lifetime diagnoses, leading to a broader range of illness
severity. As subjects in need of antidepressant treatment are
usually more severely ill than non-users, this may confound
the association between antidepressants and cortisol.
However, although antidepressant users scored higher than
non-users on the IDS-SR in the present study, severity did not
confound the associations found.
Our study had several limitations. We performed a cross-
sectional analysis, which precluded causal inferences. Since
our study categorized length of use in number of months and
the majority of users reported at least two months of use, it
was not possible to evaluate cortisol levels after five or sixweeks to directly compare our results with those found in
short-term intervention studies. In addition, the ambulatory
setting and the consequent possibility of non-compliance
with instructions on saliva collection may have resulted in
measurement error. Despite these limitations, our study had
many valuable features. Our large sample size and multiple
cortisol measurements allowed us to compare sizable groups
of users of different antidepressant types on several cortisol
measures indicative of different aspects of HPA axis activity,
while adjusting for many potential confounders.
In conclusion, we found an atypical cortisol awakening
response in TCA users as well as higher basal cortisol levels
and decreased cortisol suppression for SSRI users as
compared to non-users within a sample of 1526 NESDA
participants with a lifetime disorder of depression and/or
anxiety. These findings suggest that antidepressant subtypes
may be associated with distinct alterations of the HPA axis.
Possible antidepressant-induced alterations of the HPA axis
might also affect comorbid physical diseases for which
altered cortisol levels are an underlying cause or contributor,
such as diabetes, cardiovascular disease and osteoporosis, in
subjects with anxiety and depression (Bruehl et al., 2007;
Nieman, 2007).
Further research on these effects in randomized trials and
prospective cohort studies may lead to a better understand-
ing of the varied efficacies of antidepressants and more
effective drug treatments for anxious and depressed
patients.
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